Biocon (NSE:BIOCON, BOM:532523) subsidiary, Biocon Biologics, has settled patent litigation with Amgen in the U.S. District Court of New Jersey, enabling the launch of its denosumab biosimilars, Bosaya and Aukelso, from Oct. 1, according to an Indian bourse filing on Wednesday.

Both products, approved by the US FDA in September with provisional interchangeability, are biosimilars to Amgen's Prolia and Xgeva used for osteoporosis and cancer-related bone conditions.

Settlement terms remain confidential.

Biocon shares rose over 1% in early trade.